Cancer clinical trials in the region Auvergne-Rhône-Alpes
507 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Lung cancer
#NCT05732831
#2022-502645-99-00
Cohortes cancer du poumon
Required histologic types
SCLC (Small Cell Lung Cancer)
NSCLC (Non-Small Cell Lung Cancer)
Mesothelium
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MTAP
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Tango Therapeutics
Phase 2
Breast cancer
#NCT05800275
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
11 recruiting sites
UNICANCER
Phase 2
Brain tumors / Central nervous system tumors
#NCT04945148
#2024-511026-31-01
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Surgery
Excluded genetic anomalies
IDH1/2
5 recruiting sites
Hopital Foch
Phase 2
Lymphoma
#NCT05463263
Required histologic types
B cell lymphoma
T cell lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Step Pharma, SAS
Phase 2
Brain tumors / Central nervous system tumors
#NCT02394626
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
1
Required previous treatments
Surgery
Radiotherapy
8 recruiting sites
Insel Gruppe AG, University Hospital Bern
Phase 2
Endometrial cancer
#NCT05548296
#2025-524542-10-00
Required histologic sub types
Serous adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Acrivon Therapeutics
Phase 2
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06906341
#2024-517432-21-00
Bras A (Cancer de l'ovaire résistant au platine)
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required platino resistance
Recurrence within 6 months after platinum-based tr...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Corcept Therapeutics
Phase 2
Multiple myeloma
#NCT07227311
#2025-523117-28-00
Cohorte BVd (Belantamab mafodotin + Bortezomib + Dexamethasone)
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
6 recruiting sites
GlaxoSmithKline
Phase 2
Multiple myeloma
#NCT07227311
#2025-523117-28-00
Cohorte BKd (Belantamab mafodotin + Carfilzomib + dexaméthasone)
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
6 recruiting sites
GlaxoSmithKline
Phase 2
Multiple myeloma
#NCT07227311
#2025-523117-28-00
Cohorte BPd (Belantamab + Pomalidomide + Dexamethasone))
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
Required previous treatments
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
6 recruiting sites
GlaxoSmithKline